Editorials

Treatment of sleep disorders with melatonin

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6968 (Published 05 November 2012) Cite this as: BMJ 2012;345:e6968
  1. Alexander Lerchl, professor of biology1,
  2. Russel J Reiter, professor2
  1. 1Jacobs University Bremen, D-28759 Bremen, Germany
  2. 2University of Texas Health Science Center, San Antonio, TX, USA
  1. a.lerchl{at}jacobs-university.de

Children with neurodevelopmental disability sleep better but may wake earlier

Melatonin (N-acetyl-5-methoxytryptamin) is synthesized in the pineal body exclusively during periods of darkness. It plays an important role in initiating and maintaining sleep. In elderly people, concentrations of endogenous melatonin usually decline, and this is often associated with insomnia.1 Treatment with melatonin is effective in restoring normal sleep and improving quality of life in people over 55 years of age.1 Melatonin has also been used to treat children with developmental disabilities and sleep difficulties. It has been shown to be preferable to hypnotics, such as clonidine and benzodiazepines, because it does not affect sleep architecture or have adverse side effects.2 3 4

In a linked research paper (doi:10.1136/bmj.e6664) Gringras and colleagues randomised 146 children with neurodevelopmental delay and other diseases (epilepsy or autistic …

Sign in

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe